NCT05280626 2022-03-15First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPInnovent Biologics (Suzhou) Co. Ltd.Phase 2 Not yet recruiting100 enrolled